The IMF of Extremely Metal-Poor Stars and the Probe into the Star-Formation Process of the Milky Way

We discuss the star formation history of the Galaxy, based on the observations of extremely metal-poor stars (EMP) in the Galactic halo, to gain an insight into the evolution and structure formation in the early universe. The initialmass function (IMF) of EMP stars is derived from the observed fraction of carbon-enhanced EXP (CEMP) stars among the EMP survivors, which are thought to originate from the evolution in the close binary systems with mass transfer. Relying upon the theory of the evolution of EMP stars and of their binary evolution, we find that stars of metallicity [Fe/H]<-2.5 were formed at typical mass of ~10M_sun. The top heavy IMF thus obtained is applied to study the early chemical evolution of the Galaxy. We construct the merging history of our Galaxy semi-analytically and derive the metallicity distribution function (MDF) of low-mass EMP stars that survive to date with taking into account the contribution of binary systems. It is shown that the resultant MDF can well reproduce the observed distribution of EMP survivors, and, in particular, that they almost all stem from a less-mass companion in binary systems. We also investigate how first stars affect the MDF of EMP stars.Comment: 5 pages, 4 figures, conference proceedings of First Star II

Cluster Morphologies as a Test of Different Cosmological Models

We investigate how cluster morphology is affected by the cosmological constant in low-density universes. Using high-resolution cosmological N-body/SPH simulations of flat (\Omega_0 = 0.3, \lambda_0 = 0.7, \Lambda CDM) and open (\Omega_0 = 0.3, \lambda_0 = 0, OCDM) cold dark matter universes, we calculate statistical indicators to quantify the irregularity of the cluster morphologies. We study axial ratios, center shifts, cluster clumpiness, and multipole moment power ratios as indicators for the simulated clusters at z=0 and 0.5. Some of these indicators are calculated for both the X-ray surface brightness and projected mass distributions. In \Lambda CDM all these indicators tend to be larger than those in OCDM at z=0. This result is consistent with the analytical prediction of Richstone, Loeb, & Turner, that is, clusters in \Lambda CDM are formed later than in OCDM, and have more substructure at z=0. We make a Kolmogorov-Smirnov test on each indicator for these two models. We then find that the results for the multipole moment power ratios and the center shifts for the X-ray surface brightness are under the significance level (5%). We results also show that these two cosmological models can be distinguished more clearly at z=0 than z = 0.5 by these indicators.Comment: 30pages, 6figures, Accepted for publication in Ap

Inflammation Among Women With a History of Gestational Diabetes Mellitus and Diagnosed Diabetes in the Third National Health and Nutrition Examination Survey

OBJECTIVE—We compared inflammatory markers among women with a history of gestational diabetes mellitus (hGDM), women with diagnosed diabetes, and unaffected women in a population-based sample

Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo

AbstractSpecific inhibitors for cathepsin L and cathepsin S have been developed with the help of computer-graphic modeling based on the stereo-structure. The common fragment, N-(L-trans-carbamoyloxyrane-2-carbonyl)-phenylalanine-dimethylamide, is required for specific inhibition of cathepsin L. Seven novel inhibitors of the cathepsin L inhibitor Katunuma (CLIK) specifically inhibited cathepsin L at a concentration of 10−7 M in vitro, while almost no inhibition of cathepsins B, C, S and K was observed. Four of the CLIKs are stable, and showed highly selective inhibition for hepatic cathepsin L in vivo. One of the CLIK inhibitors contains an aldehyde group, and specifically inhibits cathepsin S at 10−7 M in vitro

Formation History of Metal-Poor Halo Stars with Hierarchical Model and the Effect of ISM accretion on the Most Metal-Poor Stars

We investigate the star formation and chemical evolution in the early universe by considering the merging history of the Galaxy in the {\Lambda}CDM scenario according to the extended Press-Schechter theory. We give some possible constraints from comparisons with observation of extremely metal-poor (EMP) stars. We demonstrate that (1) The hierarchical structure formation can explain the characteristics of the observed metallicity distribution function (MDF) including a break around [Fe/H]~-4. (2) A high mass IMF of peak mass ~10Msun with the contribution of binaries, derived from the statistics of carbon enhanced EMP stars (Komiya et al. 2007), predicts the frequency of low-mass survivors consistent with the number of EMP stars observed for -4~<[Fe/H]~<-2.5. (3) The stars formed from primordial gas before the first supernova explosions in their host mini-halos are assigned to the HMP stars with [Fe/H]~-5. (4) There is no indication of significant changes in the IMF and the binary contribution at metallicity -4~<[Fe/H]~<-2.5, or even larger as long as the field stars of Galactic halo are concerned. We further study the effects of the surface pollution through the accretion of ISM along the chemical and dynamical evolution of the Galaxy for low-mass Pop.III and EMP survivors. Because of shallower potential of smaller halos, the accretion of ISM in the mini-halos in which these stars were born dominates the surface metal pollution. This can account for the surface iron abundances as observed for the HMP stars if the cooling and concentration of gas in their birth mini-halos is taken into account. We also study the feedback effect from the very massive Pop. III stars. The metal pre-pollution by PISNe is shown to be compatible with the observed lack of their nucleosynthetic signatures when some positive feedback on gas cooling works and changes IMF from being very massive to being high mass.Comment: 20 pages, 14 figures. ApJ accepte

Tunneling Desorption of Single Hydrogen on the Surface of Titanium Dioxide

We investigated the reaction mechanism of the desorption of single hydrogen from a titanium dioxide surface excited by the tip of a scanning tunneling microscope (STM). Analysis of the desorption yield, in combination with theoretical calculations, indicates the crucial role played by the applied electric field. Instead of facilitating desorption by reducing the barrier height, the applied electric field causes a reduction in the barrier width, which, when coupled with the electron excitation induced by the STM tip, leads to the tunneling desorption of the hydrogen. A significant reduction in the desorption yield was observed when deuterium was used instead of hydrogen, providing further support for the tunneling-desorption mechanism

Whole-genome sequencing of Theileria parva strains provides insight into parasite migration and diversification in the african continent

The disease caused by the apicomplexan protozoan parasite Theileria parva, known as East Coast fever or Corridor disease, is one of the most serious cattle diseases in Eastern, Central, and Southern Africa. We performed whole-genome sequencing of nine T. parva strains, including one of the vaccine strains (Kiambu 5), field isolates from Zambia, Uganda, Tanzania, or Rwanda, and two buffalo-derived strains. Comparison with the reference Muguga genome sequence revealed 34 814–121 545 single nucleotide polymorphisms (SNPs) that were more abundant in buffalo-derived strains. High-resolution phylogenetic trees were constructed with selected informative SNPs that allowed the investigation of possible complex recombination events among ancestors of the extant strains. We further analysed the dN/dS ratio (non-synonymous substitutions per non-synonymous site divided by synonymous substitutions per synonymous site) for 4011 coding genes to estimate potential selective pressure. Genes under possible positive selection were identified that may, in turn, assist in the identification of immunogenic proteins or vaccine candidates. This study elucidated the phylogeny of T. parva strains based on genome-wide SNPs analysis with prediction of possible past recombination events, providing insight into the migration, diversification, and evolution of this parasite species in the African continent

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis

Summary: The MOVEST study evaluated the efficacy and safety of monthly oral ibandronate versus licensed monthly IV ibandronate in Japanese osteoporotic patients. Relative BMD gains after 12 months were 5.22 % oral and 5.34 % IV, showing non-inferiority of oral to IV ibandronate (primary endpoint). No new safety concerns were identified. Introduction: The randomized, phase 3, double-blind MOVEST (Monthly Oral VErsus intravenouS ibandronaTe) study evaluated the efficacy and safety of monthly oral ibandronate versus the licensed monthly intravenous (IV) ibandronate regimen in Japanese patients with osteoporosis. Methods: Ambulatory patients aged ?55 years with primary osteoporosis were randomized to receive oral ibandronate 100 mg/month plus monthly IV placebo, or IV ibandronate 1 mg/month plus monthly oral placebo. The primary endpoint was non-inferiority of oral versus IV ibandronate with respect to bone mineral density (BMD) gains at the lumbar spine after 12 months of treatment. Results: Four hundred twenty-two patients were enrolled with 372 patients in the per-protocol set (183 and 189 in the oral and IV ibandronate groups, respectively). The relative change from baseline in lumbar spine BMD values for the oral and IV ibandronate groups, respectively, was 5.22 % (95 % confidence interval [CI] 4.65, 5.80) and 5.34 % (95 % CI 4.78, 5.90). The least squares mean difference between the two groups was ?0.23 % (95 % CI ?0.97, 0.51), showing non-inferiority of oral ibandronate to IV ibandronate (non-inferiority limit = ?1.60). Changes in BMD values at other sites, and bone turnover marker levels in the oral ibandronate group, were comparable with those of the IV group. The safety profile was similar to that previously demonstrated; no new safety concerns were identified. Conclusions: This study demonstrated the non-inferiority of oral ibandronate 100 mg/month to IV ibandronate 1 mg/month (licensed dose in Japan) in increasing lumbar spine BMD in Japanese patients with primary osteoporosis